Merit Medical Systems, Inc. (NASDAQ:MMSI) COO Ronald Frost sold 5,257 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $61.31, for a total value of $322,306.67. Following the sale, the chief operating officer now owns 5,257 shares in the company, valued at approximately $322,306.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Ronald Frost also recently made the following trade(s):
- On Friday, November 16th, Ronald Frost sold 4,743 shares of Merit Medical Systems stock. The shares were sold at an average price of $61.30, for a total value of $290,745.90.
NASDAQ MMSI traded down $0.15 on Monday, reaching $62.90. 251,200 shares of the stock traded hands, compared to its average volume of 391,914. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.47 and a current ratio of 2.77. The firm has a market cap of $3.46 billion, a P/E ratio of 49.14, a PEG ratio of 2.90 and a beta of 1.22. Merit Medical Systems, Inc. has a 12 month low of $41.55 and a 12 month high of $66.34.
Large investors have recently made changes to their positions in the company. First Hawaiian Bank acquired a new stake in shares of Merit Medical Systems during the 3rd quarter valued at $107,000. Alpha Cubed Investments LLC acquired a new stake in shares of Merit Medical Systems during the 3rd quarter valued at $211,000. Creative Planning acquired a new stake in shares of Merit Medical Systems during the 3rd quarter valued at $221,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Merit Medical Systems during the 2nd quarter valued at $206,000. Finally, Mutual Advisors LLC acquired a new stake in shares of Merit Medical Systems during the 2nd quarter valued at $208,000. Institutional investors own 96.19% of the company’s stock.
Several research firms have recently commented on MMSI. Zacks Investment Research lowered Merit Medical Systems from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. Barrington Research upped their target price on Merit Medical Systems to $69.00 and gave the company an “outperform” rating in a report on Tuesday, October 2nd. Piper Jaffray Companies upped their target price on Merit Medical Systems from $58.00 to $72.00 and gave the company an “overweight” rating in a report on Tuesday, October 2nd. Bank of America lowered Merit Medical Systems from a “buy” rating to an “underperform” rating and set a $64.00 price objective for the company. in a report on Tuesday, August 7th. Finally, Needham & Company LLC increased their price objective on Merit Medical Systems from $67.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $68.10.
About Merit Medical Systems
Merit Medical Systems, Inc designs, develops, manufactures, and markets various disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides various peripheral intervention products, including access, angiography, intervention, and drainage and biopsy products to alleviate patients suffering from peripheral vascular and non-vascular diseases; and cardiac intervention products to aid in the treatment of various cardiac conditions specific to interventional cardiology and electrophysiology, including cardiac rhythm management and lead management.
Featured Article: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.